Skye Bioscience’s share price tumbled in pre-market trading Monday, as the biotech announced a strategic refocus in the wake of a phase 2 trial failure.

A company that makes tests for lead poisoning has agreed to resolve criminal charges that it concealed for years a malfunction that resulted in inaccurately low results.

Skye Bioscience’s share price tumbled in pre-market trading Monday, as the biotech announced a strategic refocus in the wake of a phase 2 trial failure.

Moderna’s combo flu and COVID-19 vaccine zipped through a late-stage trial this winter, and the results are showing a higher immune response than licensed comparators—including the famed biotech’s own Spikevax.

Oculis is forging ahead with its precision medicine approach to treating dry eye disease, outlining plans to finalize a phase 3 study after seeing some signs of efficacy in a subpopulation in its midstage trial.

The FDA is alerting healthcare providers to a software recall from Medtronic for its neurosurgery navigation software after reports of potentially inaccurate measurements being displayed during brain procedures.

Nearly a year after garnering an FDA nod, Abbott’s wireless, dual-chamber pacemaker system is crossing the pond with a CE Mark approval in Europe.

Moderna’s methylmalonic acidemia candidate, mRNA-3705, will be developed under the FDA’s START pilot program for rare disease, the company announced June 6.

Two major players are vying for women’s hearts, but it’s not as romantic as it sounds.

Charles River Laboratories and Sanofi are working on a new project in which virtual control animals will take the place of live ones in preclinical research, the companies announced June 5. No terms or financial details were disclosed.